

Lipoprotein-Associated Phospholipase A₂ Activity and Risk of Recurrent Stroke

Mitchell S.V. Elkind^a Wanling Tai^b Kristen Coates^a Myunghee C. Paik^b
Ralph L. Sacco^{a, c}

^aDepartment of Neurology, College of Physicians and Surgeons, Columbia University, and Columbia-Presbyterian Medical Center, New York Presbyterian Hospital, and ^bDivision of Biostatistics, Joseph P. Mailman School of Public Health, Columbia University, New York, N.Y., and ^cDepartment of Neurology, Miller School of Medicine, University of Miami, Miami, Fla., USA

Key Words

Anti-inflammatory strategies · C-reactive protein · Ischemic stroke · Lipoprotein-associated phospholipase A₂ · Pro-inflammatory mediators · Recurrent stroke

Abstract

Background: Mass levels of lipoprotein-associated phospholipase A₂ (Lp-PLA₂), a leukocyte-derived enzyme involved in the metabolism of low-density lipoprotein to pro-inflammatory mediators, are associated with prognosis after stroke. Lp-PLA₂ mass correlates only moderately with levels of Lp-PLA₂ activity. The relationship of Lp-PLA₂ activity to risk of stroke recurrence is unknown. We hypothesized that Lp-PLA₂ activity levels would predict risk of recurrence. **Methods:** In the population-based Northern Manhattan Stroke Study, first ischemic stroke patients ≥40 years were followed for recurrent stroke. Levels of Lp-PLA₂ activity were assessed in 467 patients, and categorized by quartile. Cox proportional hazard models were used to calculate hazard ratios (HR) and 95% confidence intervals (95% CI) for risk of recurrent stroke associated with marker quartiles after adjusting for demographics, vascular risk factors, and high-sensitivity C-reactive protein (hsCRP). **Results:** Mean age was 68.9 ± 12.7 years; 54.6% were women; 53.3% Hispanic, 27.2% black, and 17.8% white. Median follow-up was 4.0 years, and

there were 80 recurrent strokes. Compared to the lowest quartile of Lp-PLA₂ activity, those in the highest had an increased risk of recurrent stroke (adjusted HR 2.54, 95% CI 1.01–6.39). **Conclusion:** Stroke patients with Lp-PLA₂ activity levels in the highest quartile, compared to those in the lowest quartile, had an increased risk of recurrence after first ischemic stroke. Further studies are warranted to determine whether this biomarker has clinical utility in determining high-risk populations of stroke survivors, and whether anti-inflammatory strategies that reduce levels of activity of Lp-PLA₂ reduce the risk of stroke recurrence.

Copyright © 2008 S. Karger AG, Basel

Introduction

Inflammation appears to play an important role in atherosclerosis and its clinical sequelae, including myocardial infarction (MI) and stroke [1]. Peripheral blood markers of inflammation, including leukocyte count, high-sensitivity C-reactive protein (hsCRP), and others, are associated with carotid atherosclerosis and predict incident stroke [2–12]. The activity of lipoprotein-associated phospholipase A₂ (Lp-PLA₂), a leukocyte-derived enzyme involved in the metabolism of low-density lipo-

protein (LDL) to pro-inflammatory mediators, has also been shown in prospective studies to predict incident stroke independently of hsCRP [13, 14].

The role of elevated levels of markers of inflammation in predicting prognosis after a first ischemic stroke is less clear, although growing evidence suggests a potential role for several inflammatory biomarkers [15, 16]. We have previously shown that leukocyte count [17] predicts recurrent stroke or death after a first ischemic stroke, and that levels of Lp-PLA₂ mass predict risk of recurrent stroke [18]. We have also reported that hsCRP predicts death after stroke [18]. Recently, a secondary analysis of the PROVE IT trial (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction) [19] demonstrated that elevated levels of Lp-PLA₂ activity, but not mass, measured 30 days after acute coronary syndromes were associated with recurrent cardiovascular events.

We hypothesized that relative elevations in Lp-PLA₂ activity at the time of a first ischemic stroke would be associated with an increased risk of recurrent stroke among an elderly, urban, multi-ethnic population after adjusting for conventional stroke risk factors and levels of hsCRP.

Patients and Methods

The Northern Manhattan Stroke Study includes a population-based incident ischemic stroke follow-up study designed to determine predictors of stroke recurrence and prognosis in a multi-ethnic, urban population. Northern Manhattan consists of the area north of 145th Street, south of 218th Street, bordered on the west by the Hudson River, and on the east by the Harlem River. The race-ethnic mixture of the community consists of approximately 60% Hispanic, 20% non-Hispanic black, and 20% non-Hispanic white residents [20, 21].

Selection of the Stroke Cohort

The methods of patient identification and enrollment have been described previously [22, 23]. Briefly, stroke patients were enrolled if they: (1) were diagnosed with a first stroke; (2) were age 40 and over, and (3) resided in Northern Manhattan for ≥ 3 months in a household with a telephone. For this analysis, only ischemic stroke cases were included. Over 80% of the patients with acute ischemic stroke in Northern Manhattan are hospitalized at the Columbia University Medical Center (CUMC). Subjects hospitalized at other local hospitals were identified through active surveillance of admissions to those hospitals and through agreements with local physicians. Approximately 5% of incident ischemic stroke patients in Northern Manhattan are not hospitalized [23]. Evaluation of patients was performed at the hospital; those subjects either not hospitalized or hospitalized elsewhere were evaluated in the outpatient research clinic. The study was approved by the CUMC Institutional Review Board. All participants gave consent directly or through a surrogate when appropriate.

Index Evaluation of Subjects

Data were collected through interviews by trained research assistants, and physical and neurological examinations were conducted by study neurologists. When possible, data were obtained directly from subjects using the standardized data collection instruments. When the subject was unable to provide answers, a proxy knowledgeable about the subject's history was interviewed. Assessments were conducted in English or Spanish depending upon the primary language of the participant. Race/ethnicity was based upon self-identification through a series of interview questions modeled after the US census and conforming to the standard definitions outlined by Directive 15 [24]. All participants identifying themselves as Hispanic were classified as such. All participants classifying themselves as white without any Hispanic origin, or black without any Hispanic origin were classified as white, non-Hispanic, or black, non-Hispanic residents, respectively.

Standardized questions were adapted from the Behavioral Risk Factor Surveillance System [25] of the Centers for Disease Control and Prevention. Standard techniques were used to measure blood pressure, height, weight, and fasting glucose and lipid panels as described previously [22, 23]. Hypertension was defined as in prior publications [22, 23], and diabetes mellitus was defined by a fasting blood glucose level ≥ 126 mg/dl, the subject's self-report of such a history, or insulin or oral hypoglycemic use.

Stroke severity was assessed using the National Institutes of Health Stroke Scale. Assessment of stroke subtype using modified TOAST (Trial of Org 10172 in Acute Stroke Treatment) criteria [26] was determined by a consensus of stroke neurologists, using all available information, as described previously [27].

Assessment of Lp-PLA₂ Activity and hsCRP

Blood samples were collected at the time of hospitalization or clinic visit in 5-ml serum separator tubes by a trained phlebotomist. Samples were centrifuged at 3,000 g for 15 min and then the serum was aliquotted into 2-ml Eppendorf tubes. Samples were then stored at -80°C until analyses were run. Serum samples were assayed for levels of Lp-PLA₂ activity using a colorimetric assay (diaDexus, South San Francisco, Calif., USA) [28, 29]. hsCRP was measured using an enzyme-linked immunoassay (BioCheck, Foster City, Calif., USA). Assays were run at a central laboratory at diaDexus. Laboratory personnel were blinded to all patient clinical data and outcomes.

Quality control was maintained by the laboratory using standard procedures, and 24% of the total samples were run in duplicate. The average coefficient of variation was 2.74%. In total, 98.4% of samples produced coefficients of variation $\leq 10\%$ between duplicates.

Follow-Up and Outcome Assessment

Follow-up evaluations were conducted at 6 months by telephone and then annually in person for 5 years. Information on vital status, functional status, and intercurrent symptoms, illness, or hospitalization was collected, as well as measurement of vital signs, and physical and neurological examination. Patients unable or unwilling to come to the CUMC were visited by a member of the research staff, and the evaluation was conducted at home or in an alternative place of residence (e.g. nursing home). An ongoing surveillance system of admissions to the CUMC and other local hospitals, described previously [30], was also used to iden-

tify study participants who experienced recurrent stroke, MI, hospitalization, or death. When available, medical records were reviewed for all outcome events including death. All outcome events were reviewed by a research assistant. MI was validated by review by a study cardiologist, and strokes by a study neurologist. Deaths were also validated by a study physician.

Statistical Analyses

Descriptive statistics were calculated among the cohort of stroke patients. Means for continuous variables and proportions for dichotomous variables were compared using t tests and χ^2 tests, as appropriate. Values for hsCRP were log transformed. Correlations between Lp-PLA₂ activity levels and other prognostic factors were also calculated. After examining the distributions, Lp-PLA₂ activity levels were categorized by quartile for further analyses. Cox proportional hazard models were then constructed to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the effect of these markers on independent risks of recurrent stroke and on a combined ischemic event outcome of recurrent stroke, MI, or vascular death. Time to first event was analyzed with censoring at the time to either non-vascular death or last follow-up. Unadjusted models, and models adjusted for demographic characteristics (age, sex, and race/ethnicity) and risk factors (coronary artery disease, diabetes mellitus, hypertension, hyperlipidemia, atrial fibrillation, and smoking), and hsCRP quartile were calculated. Because a previous study had indicated that the effect of Lp-PLA₂ mass differed in those with LDL \geq 130 mg/dl [31], an interaction term for LDL \geq 130 mg/dl was also included. The final models were tested to ensure that they satisfied assumptions of proportionality. Analyses including death were additionally adjusted by stroke severity. Because this was a post hoc analysis of a previously assembled cohort, power was not formally calculated prospectively. Statistical analyses were conducted using SAS software (version 8.2; SAS Institute, Cary, N.C., USA).

Results

Study Population

The total Northern Manhattan Stroke Study cohort included 655 incident ischemic stroke patients, as described previously [17]. Measurements of Lp-PLA₂ activity were available for this analysis in 467 participants. The distribution of sociodemographic factors, comorbid vascular diseases, and conventional atherosclerotic risk factors is shown in table 1. Differences between this sample and the overall cohort have been described previously [18]. Briefly, the sample with Lp-PLA₂ activity measurements available was slightly younger than those of the patients who did not have these measurements made: 68.9 ± 12.7 compared to 71.9 ± 12.4 years ($p = 0.006$). There were no significant differences between the groups in sex, race/ethnicity, or any risk factors. By logistic modeling, the probability of selection was also shown to be independent of recurrent stroke, conditioning on other

Table 1. Characteristics of the participants

Participants, n	467
Demographics	
Age, years	68.9 ± 12.7
Male	212 (45.4)
High school education	160 (34.9)
Non-Hispanic white	83 (17.8)
Non-Hispanic black	127 (27.2)
Hispanic	249 (53.3)
Other	8 (1.7)
Risk factors	
Hypertension	317 (67.9)
Diabetes mellitus	150 (32.2)
History of MI	74 (15.9)
History of coronary artery disease	160 (34.3)
History of congestive heart failure	62 (13.3)
History of atrial fibrillation	50 (10.7)
History of peripheral arterial disease	108 (23.2)
Current smoking	101 (22.7)
Ever smoked	250 (53.8)
History of hypercholesterolemia	171 (36.9)
Total cholesterol, mg/dl (n = 461)	192.2 ± 45.0
LDL, mg/dl (n = 452)	121.3 ± 39.3
HDL, mg/dl (n = 459)	39.7 ± 12.0
LDL >130 mg/dl (3.37 mmol/l; n = 452)	170 (37.6)
HDL <40 mg/dl (1.04 mmol/l; n = 459)	274 (58.7)
Stroke: etiologic subtypes (n = 464)	
Atherosclerotic	77 (16.5)
Lacunar	109 (23.3)
Cardioembolic	86 (18.4)
Cryptogenic	195 (41.7)
Stroke severity (n = 455)	
NIHSS score 0–5	237 (52.1)
NIHSS score 6–13	154 (33.9)
NIHSS score \geq 14	64 (14.1)

Hypertension was defined as a systolic blood pressure recording \geq 140 mm Hg or a diastolic blood pressure recording \geq 90 mm Hg, or the patient's self-report of a history of hypertension or antihypertensive use. Diabetes mellitus was defined by a fasting blood glucose level >126 mg/dl, the patient's self-report of such a history, or insulin or hypoglycemic use. Not all data were available for all participants. Cryptogenic subtype includes 180 cryptogenic strokes after full evaluation, 14 conflicting mechanisms, and 1 other mechanism. HDL = High-density lipoprotein; NIHSS = National Institutes of Health Stroke Scale. Means \pm SD and numbers (%) of patients are shown.

covariates (age, sex, race/ethnicity, diabetes mellitus, hypertension, hyperlipidemia, atrial fibrillation, current smoking, and coronary artery disease).

Blood samples were drawn at the time of admission (\leq 72 h after stroke onset in 83.7% of patients and \leq 6 days in 90.0% of patients). Lp-PLA₂ activity levels were

normally distributed (mean 123.9 ± 35.2 nmol/min/ml; median 120.4 nmol/min/ml; fig.1). Lp-PLA₂ activity was moderately correlated with Lp-PLA₂ mass ($R = 0.60$, $p < 0.0001$). Lp-PLA₂ activity levels after stroke were associated with age, sex, race/ethnicity, and a history of diabetes mellitus, but not with stroke severity, history of coronary artery disease, hypertension, atrial fibrillation, or current smoking (table 2).

Lp-PLA₂ Activity as a Predictor of Outcome

Median follow-up was 4.0 years. Outcomes included 80 recurrent strokes, including 15 fatal recurrent strokes. In addition, there were 18 MIs, and 53 non-stroke-related vascular deaths. In an unadjusted model using the lowest quartile as a reference group, the highest quartile of Lp-PLA₂ activity was significantly associated with risk of recurrent stroke (HR 2.09, 95% CI 1.07–4.08; table 3). The second and third quartiles were not associated with any increased risk (table 3).

Because a prior study had indicated that the effect of Lp-PLA₂ mass in predicting prognosis after cardiac events was attenuated in those with LDL ≥ 130 mg/dl [31], evidence of an interaction with LDL was sought. There was a suggestion of an interaction between Lp-PLA₂ and LDL ≥ 130 mg/dl ($p = 0.10$), and an interaction term was therefore kept in the final model. After adjusting for age, sex, race/ethnicity, history of hypertension, diabetes mellitus, hyperlipidemia, smoking, coronary artery disease, hsCRP, and the interaction with LDL ≥ 130 mg/dl, those in the highest quartile of Lp-PLA₂ activity continued to have an increased risk of recurrent stroke (adjusted HR 2.54, 95% CI 1.01–6.39). Further adjusting for time from stroke onset to time of blood sampling did not change the results. While there was evidence of an effect of Lp-PLA₂ activity on stroke recurrence risk in those with LDL < 130 mg/dl, no definite evidence of an effect in those with LDL ≥ 130 mg/dl was found ($p = 0.313$).

Receiver operator curves (ROC) were constructed and area under the curve (AUC) calculated to assess for the additional information gained by inclusion of Lp-PLA₂ activity in prediction of risk of stroke recurrence (fig. 2). These curves were also compared to ROC curves for models including Lp-PLA₂ mass. Addition of Lp-PLA₂ activity to the model including all other risk factors but Lp-PLA₂ activity led to a slight increase in AUC from 0.646 to 0.668. The increase in AUC was less than that for inclusion of Lp-PLA₂ mass levels, which increased from 0.612 to 0.652.

Only 12% of patients in this sample were taking cholesterol-lowering medications, including statins, prior to their stroke, based on the interviews at the time of entry




Fig. 1. Distribution of Lp-PLA₂ activity levels in the cohort.

Table 2. Lp-PLA₂ activity levels and patient characteristics

	n	Lp-PLA ₂ activity	
		nmol/min/ml	p value
Overall		123.9 ± 35.2	–
Age			
<70 years	243	119.3 ± 34.2	0.0034
>70 years	224	128.8 ± 35.7	
Sex			
Men	212	130.0 ± 33.1	0.0005
Women	255	118.7 ± 36.1	
Race/ethnicity			
NH white	83	143.0 ± 34.9	<0.0001
NH black	127	119.7 ± 34.9	
Hispanic	249	119.3 ± 33.7	
Other	8	131.8 ± 26.5	
Risk factors			
Diabetes	316	126.6 ± 35.8	0.015
No diabetes	150	118.1 ± 33.6	
Hypertension	317	121.8 ± 34.6	0.066
No hypertension	150	128.2 ± 36.1	
Hyperlipidemia	147	122.8 ± 32.9	0.692
No hyperlipidemia	317	124.2 ± 36.4	
Currently smoking	101	125.6 ± 39.3	0.536
Not currently smoking	345	123.0 ± 34.6	
Atrial fibrillation	50	126.8 ± 32.5	0.526
No atrial fibrillation	416	123.5 ± 35.6	
History of CAD	160	127.9 ± 35.0	0.075
No history of CAD	307	121.8 ± 35.2	
Stroke severity			
NIHSS score <6	237	122.8 ± 32.6	0.676
NIHSS score 6–13	154	124.9 ± 36.5	
NIHSS score ≥ 14	64	126.8 ± 42.2	

NH = Non-Hispanic; CAD = coronary artery disease; NIHSS = National Institutes of Health Stroke Scale.




Fig. 2. **a** ROC for model containing age, sex, race/ethnicity, history of hypertension, diabetes mellitus, hyperlipidemia, smoking, coronary artery disease, hsCRP, and LDL. **b** ROC for model containing covariates in **a** and Lp-PLA₂ and the interaction between LDL \geq 130 mg/dl and Lp-PLA₂.

Table 3. Lp-PLA₂ activity levels as predictors of outcome after first ischemic stroke

	Lp-PLA ₂ activity			
	quartile 1 0–98.7 nmol/ min/ml	quartile 2 98.8–120.4 nmol/min/ml	quartile 3 120.5–145.4 nmol/min/ml	quartile 4 \geq 145.5 nmol/ min/ml
Recurrent stroke, HR (95% CI)				
Unadjusted	1.0	1.66 (0.83–3.31)	1.57 (0.78–3.16)	2.09 (1.07–4.08)
Adjusted ¹	1.0	1.19 (0.47–3.01)	0.91 (0.30–2.78)	2.54 (1.01–6.39)
Recurrent stroke/MI/vascular death, HR (95% CI)				
Unadjusted	1.0	1.51 (0.88–2.59)	1.45 (0.84–2.50)	1.76 (1.03–2.99)
Adjusted ²	1.0	1.24 (0.61–2.53)	1.04 (0.45–2.40)	1.69 (0.76–3.76)

¹ Adjusted for age, sex, race/ethnicity, history of hypertension, diabetes mellitus, hyperlipidemia, smoking, coronary artery disease, hsCRP, LDL, and the interaction with LDL \geq 130 mg/dl.

² Adjusted for age, sex, race/ethnicity, history of hypertension, diabetes mellitus, hyperlipidemia, smoking, coronary artery disease, hsCRP, LDL, stroke severity, and the interaction with LDL \geq 130 mg/dl.

into the study. We did not have systematic data collected on use of statins after stroke, during follow-up. Analyses including cholesterol-lowering medication use at the time of stroke as a covariate showed minimal change in the magnitude of the HR (2.36, 95% CI 0.86–6.51). In addition, stratified analyses were performed to assess the differential effects of Lp-PLA₂ in atherosclerotic and non-atherosclerotic subtypes of stroke. While the number of patients with stroke subtypes was too small to draw definitive conclusions, there was a suggestion of a greater

effect on risk of stroke recurrence among those with atherosclerotic stroke (adjusted HR 1.81, 95% CI 0.45–7.25) versus non-atherosclerotic stroke (adjusted HR 0.84, 95% CI 0.31–2.26).

hsCRP was not associated with an increased risk of recurrent stroke (adjusted HR 0.72, 95% CI 0.36–1.45) in the fully adjusted model.

Although in an unadjusted model Lp-PLA₂ activity was associated with the composite secondary outcome of recurrent stroke, MI, or vascular death, activity levels

were not associated with the secondary outcome after adjusting for other covariates, including stroke severity (adjusted HR for highest versus lowest quartile 1.69, 95% CI 0.76–3.76).

Discussion

Inflammatory markers predict incident ischemic events, including MI and stroke, in many studies, but their ability to predict prognosis after ischemic stroke remains uncertain [32]. We have previously reported that levels of hsCRP predict mortality after stroke and that Lp-PLA₂ mass levels predict recurrent stroke and other ischemic events [18]. In the present study, we found that Lp-PLA₂ activity levels in the top quartile also predict recurrent stroke, but not ischemic events overall. Patients in the highest quartile of Lp-PLA₂ activity had approximately 2.5 times the risk of stroke recurrence as those in the first quartile, even after adjusting for other risk factors, though there is a 95% chance that the true increased risk could be ~1.01–6.39 times as high. The effect on risk appeared to be greater for those with atherosclerotic stroke, although numbers of patients with stroke subtypes were too small to draw definitive conclusions about the effect in subtypes.

Lp-PLA₂, an enzyme derived from leukocytes, particularly macrophages, is responsible for metabolism of LDL to the pro-inflammatory mediators lysophosphatidylcholine and oxidized fatty acids [33]. Lysophosphatidylcholine increases expression of vascular adhesion molecules, upregulates cytokines and CD40 ligand, and stimulates macrophage proliferation [34]. Levels of Lp-PLA₂ activity have been associated with increased risk of incident ischemic cardiac and cerebrovascular events in epidemiological studies [13]. Our study provides evidence that this novel marker of vascular inflammatory activity is associated with risk of recurrent stroke in patients after first stroke. Levels of Lp-PLA₂ activity, like those of Lp-PLA₂ mass, were not markedly affected by stroke severity in our population.

Most studies of Lp-PLA₂ have focused on enzyme mass levels rather than activity. The current commercially available assay tests mass only. Lp-PLA₂ mass and activity levels are incompletely correlated, however, probably because the assays measure different populations of the enzyme in serum related to binding to specific lipoprotein subfractions. The assay we used, moreover, has a high concentration of 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate, which acts as a detergent

and minimizes measurement error due to presence of other lipases [28]. Other studies have found correlations ranging from $r = 0.36$ in the large PROVE IT trial [19] to $r = 0.89$ in an earlier, smaller study among men only [35]. The correlation in our study ($r = 0.60$) is intermediate between these values. These differences are likely attributable to the different assays used to measure Lp-PLA₂ activity. In our cohort, mean levels of Lp-PLA₂ activity were higher than those in studies using radiometric [13, 19] rather than colorimetric assays, but the mean value was very similar to that using the same colorimetric assay in a German population [28]. The correlation between mass and activity in our study ($R = 0.60$) was also very similar to that observed in the same German population ($R = 0.573$) [28]. Activity levels were significantly different between men and women in our analysis, consistent with other studies [13].

Few studies have assessed the association of outcomes with both Lp-PLA₂ mass and activity [19, 36]. In one study in which both measurements were made, mass but not activity was significantly associated with calcified coronary plaques [36]. In secondary analysis of a large cardiac prevention trial (PROVE IT), activity levels measured 30 days after an acute coronary event were associated with outcome, but mass levels measured either immediately or 30 days after the event were not [19]. Possible reasons for differences between mass and activity levels as prognostic markers include acute changes in activity levels in the setting of lipoprotein changes.

The absence of an effect of measurements of Lp-PLA₂ activity immediately after an event on prognosis in some [19], but not all [37], cardiac studies could reflect acute changes in Lp-PLA₂ activity levels, as with LDL levels, after acute coronary events because Lp-PLA₂ co-localizes with LDL. LDL levels do not appear to be influenced as strongly by stroke, however [38]. We did not have levels available at 30 days or other time points to compare.

Recently, studies in other populations have also demonstrated that Lp-PLA₂ activity levels measured in cardiac patients predict long-term risk of recurrent coronary ischemic events independently of other lipid and inflammatory biomarkers, including hsCRP and LDL [29, 39]. Mass levels were associated with a slightly greater magnitude of risk than Lp-PLA₂ activity levels in those studies, however, and remained significant after adjusting for other biomarkers. Lp-PLA₂ mass was minimally more predictive of recurrent stroke than was Lp-PLA₂ activity in our population, based on ROC analyses. Both markers, moreover, provided only a minimal incremental increase in information about risk compared with other risk fac-

tors. In this context, our results are similar to those of analyses of multiple biomarkers conducted in large epidemiological studies, in which Lp-PLA₂ mass was one of the only biomarkers to provide incremental risk information, albeit modest [40]. Nonetheless, because stroke is a prevalent, debilitating, and preventable disease, we would argue that any additional prognostic risk information can serve as a valuable adjunct to already identified risk factors.

Although further studies are needed, both to define the optimal role of Lp-PLA₂ testing in clinical practice and to determine the relative merits of mass versus activity testing, at present measurement of mass levels would seem clinically preferable for several reasons. These include the greater magnitude of effect for Lp-PLA₂ mass levels in most studies, their independent predictive value, their ability to predict a wider variety of adverse vascular events, and the availability of a commercially available, standardized assay.

Lp-PLA₂ is found predominantly on LDL particles, and there is some evidence of effect modification by levels of LDL. In the ARIC (Atherosclerosis Risk in Communities) study, for example, the increased risk of incident heart disease associated with Lp-PLA₂ was limited to those with LDL levels <130 mg/dl [14]. In other studies, particularly for stroke, there was no definite interaction between Lp-PLA₂ and LDL levels [13, 14, 41]. We found evidence of a possible interaction of Lp-PLA₂ activity with LDL levels in predicting risk of recurrent stroke, similar to what was seen for incident coronary disease in ARIC. In our population, Lp-PLA₂ activity levels predicted risk of recurrent stroke in those with LDL levels <130 mg/dl, but not in those with LDL ≥130 mg/dl. Lp-PLA₂ may be a less informative biomarker when LDL is ≥130 mg/dl because at higher levels of LDL, the LDL effect overshadows any increased risk associated with Lp-PLA₂. The clinical utility of Lp-PLA₂ may therefore be greater when LDL is lower. Use of inflammatory biomarkers for prognostication among patients without otherwise-defined high-risk conditions is consistent with recommended guidelines on their use from a recent consensus conference [4]. Further studies in larger populations are needed to better define the extent of interactions between Lp-PLA₂ and lipid levels in stroke prognosis.

Our study has several limitations. We did not have blood available for analysis in all stroke patients in our cohort, but the differences between our entire cohort and the sample analyzed in this study were minimal. We also did not have available data at multiple times after stroke. Further studies are needed to determine whether assess-

ment of Lp-PLA₂ levels at longer intervals provide improved prognostic information. We also did not collect blood samples at uniform time intervals after stroke. The use of non-standardized timing of assessments of Lp-PLA₂, if random and unassociated with outcomes, would be expected to bias the results toward the null. Our study could therefore underestimate the effect of an association with outcomes. Finally, we did not have systematic data on the use of statins after stroke in this population.

In summary, our data support an association between Lp-PLA₂ activity levels in the top quartile and stroke recurrence. Further prospective studies on the role of Lp-PLA₂ activity and mass in stroke prognosis might lead to the use of these markers to improve prediction of stroke or other vascular events after stroke. Identification of those patients at increased risk could justify targeted or more aggressive treatment in these patients using other prevention modalities, such as weight loss, blood pressure reduction, or other proven risk reduction strategies. In addition, treatments that directly reduce levels of Lp-PLA₂ could potentially be tested in clinical trials to prevent incident and recurrent stroke. For example, statins may reduce Lp-PLA₂ levels [42]. Other trials, moreover, are investigating whether the risk of atherosclerotic disease is modified by use of direct inhibitors of Lp-PLA₂ [43, 44].

Acknowledgments

This work was supported by grants from the American Heart Association (Kathleen Scott Research Fellowship, M.S.V.E.), National Institute of Neurological Disorders and Stroke (R01 NS27517 and R01 NS29993, R.L.S.; and K23 42912 and R01 NS48134, M.S.V.E.), and research funding for performance of blood assays from diaDexus.

Conflict of Interest

M.S.V.E. receives research funding from diaDexus, Inc., and BMS-Sanofi Partnership, and honoraria for speaking from diaDexus, Inc., (modest) and BMS-Sanofi Partnership and Boehringer-Ingelheim (significant); R.L.S. receives honoraria for speaking from BMS-Sanofi Partnership and Boehringer-Ingelheim (modest), and serves as a consultant for BMS-Sanofi Partnership, Boehringer-Ingelheim, Merck, Wyeth, and GlaxoSmith-Kline.

References

- 1 Ross R: Atherosclerosis – an inflammatory disease. *N Engl J Med* 1999;340:115–126.
- 2 Elkind MS, Cheng J, Boden-Albala B, Paik MC, Sacco RL: Elevated white blood cell count and carotid plaque thickness: the Northern Manhattan Stroke Study. *Stroke* 2001;32:842–849.
- 3 Elkind MS, Sciacca R, Boden-Albala B, Rundek T, Paik MC, Sacco RL: Relative elevation in leukocyte count predicts first cerebral infarction. *Neurology* 2005;64:2121–2125.
- 4 Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F: Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. *Circulation* 2003;107:499–511.
- 5 Kannel WB, Anderson K, Wilson PW: White blood cell count and cardiovascular disease. Insights from the Framingham Study. *JAMA* 1992;267:1253–1256.
- 6 Di Napoli M, Schwaninger M, Cappelli R, Ceccarelli E, Di Gianfilippo G, Donati C, Emsley HC, Forconi S, Hopkins SJ, Masotti L, Muir KW, Paciucci A, Papa F, Roncacci S, Sander D, Sander K, Smith CJ, Stefanini A, Weber D: Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. *Stroke* 2005;36:1316–1329.
- 7 Ridker PM, Rifai N, Stampfer MJ, Hennekens CH: Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. *Circulation* 2000;101:1767–1772.
- 8 Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. *N Engl J Med* 1997;336:973–979.
- 9 Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *N Engl J Med* 2000;342:836–843.
- 10 Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J: Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. *Lancet* 1998;351:88–92.
- 11 Hwang S-J, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM Jr, Boerwinkle E: Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities (ARIC) study. *Circulation* 1997;96:4219–4225.
- 12 Grau AJ, Bugge F, Becher H, Werle E, Hacke W: The association of leukocyte count, fibrinogen and C-reactive protein with vascular risk factors and ischemic vascular diseases. *Thromb Res* 1996;82:245–255.
- 13 Oei HH, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MM, Witteman JC: Lipoprotein-associated phospholipase A₂ activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. *Circulation* 2005;111:570–575.
- 14 Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Chambless LE, Myerson M, Wu KK, Sharrett AR, Boerwinkle E: Lipoprotein-associated phospholipase A₂, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. *Arch Intern Med* 2005;165:2479–2484.
- 15 Castellanos M, Serena J: Applicability of biomarkers in ischemic stroke. *Cerebrovasc Dis* 2007;24(suppl 1):7–15.
- 16 Chamorro A: Role of inflammation in stroke and atherothrombosis. *Cerebrovasc Dis* 2004;17(suppl 3):1–5.
- 17 Elkind MS, Cheng J, Rundek T, Boden-Albala B, Sacco RL: Leukocyte count predicts outcome after ischemic stroke: the Northern Manhattan Stroke Study. *J Stroke Cerebrovasc Dis* 2004;13:220–227.
- 18 Elkind MS, Tai W, Coates K, Paik MC, Sacco RL: High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A₂, and outcome after ischemic stroke. *Arch Intern Med* 2006;166:2073–2080.
- 19 O'Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, Braunwald E: Lipoprotein-associated phospholipase A₂ and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. *Circulation* 2006;113:1745–1752.
- 20 United States Census of Population and Housing, 1990 (Public Use Microdata Sample). www.census.gov.
- 21 Garfield R, Abramson D (eds): *Washington Heights/Inwood: The Health of a Community. The Health of the Public Program.* New York, Columbia University, 1995.
- 22 Sacco RL, Gan R, Boden-Albala B, Lin IF, Kargman DE, Hauser WA, Shea S, Paik MC: Leisure-time physical activity and ischemic stroke risk: the Northern Manhattan Stroke Study. *Stroke* 1998;29:380–387.
- 23 Sacco RL, Elkind MS, Boden-Albala B, Lin IF, Kargman DE, Hauser WA, Shea S, Paik MC: The protective effect of moderate alcohol consumption on ischemic stroke. *JAMA* 1999;281:53–60.
- 24 Office of Management and Budget: *Race and Ethnic Standards for Federal Statistics and Administrative Reporting (Directive No. 15).* Federal Register 1978;43:19269.
- 25 Gentry EM, Kalsbeek WD, Hegelin G, et al: The behavioral risk factor surveys: II. Design, methods, and estimates from combined state data. *Am J Prev Med* 1985;1:9–14.
- 26 Adams HP Jr, Woolson RF, Clarke W, et al: Design of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). *Control Clin Trials* 1997;18:358–377.
- 27 Gan R, Sacco RL, Kargman DE, Roberts JK, Boden-Albala B, Gu Q: Testing the validity of the lacunar hypothesis: the Northern Manhattan Stroke Study experience. *Neurology* 1997;48:1204–1211.
- 28 Kosaka T, Yamaguchi M, Soda Y, Kishimoto T, Tago A, Toyosato M, Mizuno K: Spectrophotometric assay for serum platelet-activating factor acetylhydrolase activity. *Clin Chim Acta* 2000;296:151–161.
- 29 Koenig W, Twardella D, Brenner H, Rothenbacher D: Lipoprotein-associated phospholipase A₂ predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function and hemodynamic stress. *Arterioscler Thromb Vasc Biol* 2006;26:1586–1593.
- 30 Sacco RL, Boden-Albala B, Gan R, Chen X, Kargman DE, Shea S, Paik MC, Hauser WA: Stroke incidence among white, black, and Hispanic residents of an urban community: the Northern Manhattan Stroke Study. *Am J Epidemiol* 1998;147:259–268.
- 31 Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR: Lipoprotein-associated phospholipase A₂, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. *Circulation* 2004;109:837–842.

- 32 Di Napoli M, Schwaninger M, Cappelli R, Ceccarelli E, Di Gianfilippo G, Donati C, Emsley HC, Forconi S, Hopkins SJ, Masotti L, Muir KW, Paciucci A, Papa F, Roncacci S, Sander D, Sander K, Smith CJ, Stefanini A, Weber D: Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. *Stroke* 2005;36:1316–1329.
- 33 MacPhee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA, Leake DS, Milliner KJ, Patterson RA, Suckling KE, Tew DG, Hickey DM: Lipoprotein-associated phospholipase A₂, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. *Biochem J* 1999;338:479–487.
- 34 Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GD: Lipoprotein-associated phospholipase A₂ as an independent predictor of coronary heart disease. *N Engl J Med* 2000;343:1148–1155.
- 35 Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH: Lipoprotein-associated phospholipase A₂, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. *Atherosclerosis* 2000;150:413–419.
- 36 Iribarren C, Gross MD, Darbinian JA, Jacobs DR Jr, Sidney S, Loria CM: Association of lipoprotein-associated phospholipase A₂ mass and activity with calcified coronary plaque in young adults: the CARDIA study. *Arterioscler Thromb Vasc Biol* 2005;25:216–221.
- 37 Gerber Y, McConnell JP, Jaffe AS, Weston SA, Killian JM, Roger VL: Lipoprotein-associated phospholipase A₂ and prognosis after myocardial infarction in the community. *Arterioscler Thromb Vasc Biol* 2006;26:2517–2522.
- 38 Kargman DE, Tuck C, Berglund L, Lin IF, Mukherjee RS, Thompson EV, Jones J, Boden-Albala B, Paik MC, Sacco RL: Lipid and lipoprotein levels remain stable in acute ischemic stroke: the Northern Manhattan Stroke Study. *Atherosclerosis* 1998;139:391–399.
- 39 Corsetti JP, Rainwater DL, Moss AJ, Zareba W, Sparks CE: High lipoprotein-associated phospholipase A₂ is a risk factor for recurrent coronary events in postinfarction patients. *Clin Chem* 2006;52:1331–1338.
- 40 Folsom AR, Chambless LE, Ballantyne CM, et al: An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. *Arch Intern Med* 2006;166:1368–1373.
- 41 Brilakis ES, McConnell JP, Lennon RJ, Eleber AA, Meyer JG, Berger PB: Association of lipoprotein-associated phospholipase A₂ levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. *E Heart J* 2005;26:137–144.
- 42 Schaefer EJ, McNamara JR, Asztalos BF, Taylor T, Daly JA, Gleason JL, Seman LJ, Ferrari A, Rubenstein JJ: Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A₂ in patients with coronary heart disease versus control subjects. *Am J Cardiol* 2005;95:1025–1032.
- 43 Blackie JA, Bloomer JC, Brown MJ, Cheng HY, Hammond B, Hickey DM, Ife RJ, Leach CA, Lewis VA, Macphee CH, Milliner KJ, Moores KE, Pinto IL, Smith SA, Stansfield IG, Stanway SJ, Taylor MA, Theobald CJ: The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A₂. *Bioorg Med Chem Lett* 2003;13:1067–1070.
- 44 Blackie JA, Bloomer JC, Brown MJ, Cheng HY, Elliott RL, Hammond B, Hickey DM, Ife RJ, Leach CA, Lewis VA, Macphee CH, Milliner KJ, Moores KE, Pinto IL, Smith SA, Stansfield IG, Stanway SJ, Taylor MA, Theobald CJ, Whittaker CM: The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A₂ for evaluation in man. *Bioorg Med Chem Lett* 2002;12:2603–2606.